Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) immunotherapy platform. Johnson & Johnson (NYSE:JNJ) stock performance was 0.69% in last session and finished the day at $101.46. Traded volume was 5.97million shares in the last session and the average volume of the stock remained 7.75million shares. The beta of the stock remained 0.57. Johnson & Johnson (NYSE:JNJ) insider ownership is 0.02%.

Endo International PLC (NASDAQ:ENDP), a U.S. drug maker formerly based in Malvern, PA, agreed to acquire Paladin Labs, Inc., a Montreal-based company, for $1.6 billion. The acquisition resulted in an inversion transaction whereby a newly-created Irish holding company (Ireland having much lower tax rates) ending up owning both Endo and Paladin. Endo International PLC (NASDAQ:ENDP) dropped -1.13 percent to $70.59 Friday on volume of 7.25million shares. The intra-day range of the stock was $70.52 to $72.55. Endo International PLC (NASDAQ:ENDP) has a market capitalization of $10.71billion.

Drug makers are under fire as the $84,000 price tag on a new hepatitis medicine has galvanized the debate over prescription drug costs. At the heart of the latest controversy is Sovaldi, a miracle drug introduced this year and manufactured by Gilead Sciences, Inc. (NASDAQ:GILD), that cures 90 percent of Hepatitis C cases, a condition that affects 3 million people. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on May 30, 2014 reported a decrease of -1.06% to the closing price of $81.21. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $124.71billion. The overall volume in the last trading session was 11.06million shares. In its share capital, GILD has 1.54billion outstanding shares.

Competitors such as Merck Squibb Co (NASDAQ:MRK) and Bristol-Myers Squibb appear to have more promising pipelines, and that could impact Pfizer in the near future. On Friday, shares of Bristol-Myers Squibb Co (NYSE:BMY) advanced 0.44% to close the day at $49.74. Company return on investment (ROI) is 10.70% and its monthly performance is recorded as -0.70%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly revenue growth is -6.85%.